Vancouver, British Columbia – TheNewswire – February 8 , 2021 – Blackhawk Growth Corp. (CSE:BLR); (Frankfurt:0JJ); (CNSX:BLR.CN); (OTC:BLRZF) (the “Company”), has submitted the required additional information for its ExProbe SARS-CoV-2 Testing Kit Health Canada Interim Order (“IO”) Submission. The Corporation received correspondence from Health Canada on Friday, January 8th requesting additional information to be provided for its ExProbe SARS-CoV-2 Testing Kit. Health Canada provided a timeline of 10 days to submit the information with the option of (up to) a 30-day extension that the corporation acted on. Blackhawk is pleased to say all 227 pages of requested documentation have been compiled and submitted to Health Canada on the agreed upon date of February 6th 2021.
Blackhawk is also pleased to announce that it has received correspondence from Health Canada on Friday, January 29th regarding its SARS-CoV-2 IgG/IgM Rapid Test Kit application which is now “under review”. The corporation has taken the position that Health Canada is now actively reviewing the IO. The Health Canada Interim Order (“IO”) for its SARS-CoV-2 IgG / IgM Rapid Test Kit application was submitted on November 4th, 2020 requesting additional information to be provided for its ExProbe SARS-CoV-2 Testing Kit. Blackhawk is working with the manufacturer and its compliance team to ensure the requested information is provided in short-order. Health Canada has provided a timeline of 10 days to submit the information with the option of a 30-day extension if required.
Blackhawk will continue to update its shareholders as the application process with Health Canada proceeds.
Blackhawk makes no representations or provides any guarantees on Health Canada’s review timelines.
About Blackhawk Growth
Blackhawk Growth is an investment issuer looking to create substantial value for our shareholders through the acquisition and development of high growth opportunities. The company has focused its investments in the health, cannabis and CBD industries in both Canada and the United States. Its portfolio of companies include Sac Pharma, Trip Pharma, Noble Hemp, Spaced Food and NuWave Foods.
For further information please contact:
Frederick Pels, Chief Executive Officer
Cautionary Note Regarding Forward-Looking Statement
All statements in this press release, other than statements of historical fact, are “forward-looking information” with respect to the Corporation within the meaning of applicable securities laws, including with respect to completion and review by Health Canada of interim order applications. The Corporation provides forward-looking statements for the purpose of conveying information about current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. By its nature, this information is subject to inherent risks and uncertainties that may be general or specific and which give rise to the possibility that expectations, forecasts, predictions, projections or conclusions will not prove to be accurate, that assumptions may not be correct and that objectives, strategic goals and priorities will not be achieved. These risks and uncertainties include but are not limited those identified and reported in the Corporation’s public filings under the Corporation’s SEDAR profile at www.sedar.com. Although the Corporation has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors that cause actions, events or results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate as actual results and future events could differ materially from those anticipated in such statements. The Corporation disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise unless required by law.